Xoma Royalty Corp (XOMA)

$29.4

+0.56

(+1.94%)▲

Live

Performance

  • $28.91
    $29.53
    $29.40
    downward going graph

    1.67%

    Downside

    Day's Volatility :2.08%

    Upside

    0.42%

    downward going graph
  • $14.27
    $30.50
    $29.40
    downward going graph

    51.46%

    Downside

    52 Weeks Volatility :53.21%

    Upside

    3.61%

    downward going graph

Returns

PeriodXoma Royalty CorpSector (Health Care)Index (Russel 2000)
3 Months
2.83%
3.6%
0.0%
6 Months
13.87%
10.2%
0.0%
1 Year
69.65%
19.6%
0.0%
3 Years
24.21%
16.8%
-23.0%

Highlights

Market Capitalization
337.6M
Book Value
$8.57
Earnings Per Share (EPS)
-2.2
PEG Ratio
-0.42
Wall Street Target Price
83.0
Profit Margin
-119.61%
Operating Margin TTM
-9.73%
Return On Assets TTM
-6.62%
Return On Equity TTM
-17.35%
Revenue TTM
15.2M
Revenue Per Share TTM
1.32
Quarterly Revenue Growth YOY
568.6%
Gross Profit TTM
5.9M
EBITDA
-19.1M
Diluted Eps TTM
-2.2
Quarterly Earnings Growth YOY
0.37
EPS Estimate Current Year
-0.12
EPS Estimate Next Year
-0.59
EPS Estimate Current Quarter
-0.27
EPS Estimate Next Quarter
-0.61

Analyst Recommendation

Buy
    77%Buy
    22%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Xoma Royalty Corp(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
7
6
6
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 182.31%

Current $29.40
Target $83.00

Company Financials

FY18Y/Y Change
Revenue
5.3M
↓ 89.94%
Net Income
-13.3M
↓ 191.42%
Net Profit Margin
-251.8%
↓ 279.5%
FY19Y/Y Change
Revenue
18.4M
↑ 246.67%
Net Income
-7.7M
↓ 42.31%
Net Profit Margin
-41.91%
↑ 209.89%
FY20Y/Y Change
Revenue
29.4M
↑ 59.96%
Net Income
13.3M
↓ 272.75%
Net Profit Margin
45.25%
↑ 87.16%
FY21Y/Y Change
Revenue
38.2M
↑ 29.86%
Net Income
15.8M
↑ 18.8%
Net Profit Margin
41.4%
↓ 3.85%
FY22Y/Y Change
Revenue
6.0M
↓ 84.21%
Net Income
-17.1M
↓ 208.27%
Net Profit Margin
-283.79%
↓ 325.19%
FY23Y/Y Change
Revenue
4.8M
↓ 21.06%
Net Income
-40.8M
↑ 138.72%
Net Profit Margin
-858.15%
↓ 574.36%
Q1 FY23Q/Q Change
Revenue
437.0K
↓ 70.59%
Net Income
-17.7M
↑ 196.52%
Net Profit Margin
-4.1K%
↓ 3652.77%
Q2 FY23Q/Q Change
Revenue
1.7M
↑ 279.41%
Net Income
-5.4M
↓ 69.53%
Net Profit Margin
-325.69%
↑ 3729.23%
Q3 FY23Q/Q Change
Revenue
830.0K
↓ 49.94%
Net Income
-5.5M
↑ 2.02%
Net Profit Margin
-663.73%
↓ 338.04%
Q4 FY23Q/Q Change
Revenue
1.8M
↑ 120.84%
Net Income
-20.1M
↑ 265.02%
Net Profit Margin
-1.1K%
↓ 433.32%
Q1 FY24Q/Q Change
Revenue
1.5M
↓ 18.71%
Net Income
-8.6M
↓ 57.26%
Net Profit Margin
-576.85%
↑ 520.2%
Q2 FY24Q/Q Change
Revenue
11.1M
↑ 644.03%
Net Income
16.0M
↓ 285.98%
Net Profit Margin
144.19%
↑ 721.04%
FY18Y/Y Change
Total Assets
63.8M
↑ 41.95%
Total Liabilities
45.0M
↑ 14.95%
FY19Y/Y Change
Total Assets
95.7M
↑ 50.07%
Total Liabilities
51.7M
↑ 14.97%
FY20Y/Y Change
Total Assets
125.3M
↑ 30.88%
Total Liabilities
38.9M
↓ 24.89%
FY21Y/Y Change
Total Assets
166.6M
↑ 32.95%
Total Liabilities
24.7M
↓ 36.48%
FY22Y/Y Change
Total Assets
140.4M
↓ 15.72%
Total Liabilities
16.4M
↓ 33.7%
FY23Y/Y Change
Total Assets
234.3M
↑ 66.9%
Total Liabilities
145.6M
↑ 789.42%
Q1 FY23Q/Q Change
Total Assets
133.7M
↓ 4.79%
Total Liabilities
19.1M
↑ 16.92%
Q2 FY23Q/Q Change
Total Assets
125.7M
↓ 5.99%
Total Liabilities
15.5M
↓ 18.82%
Q3 FY23Q/Q Change
Total Assets
124.1M
↓ 1.25%
Total Liabilities
18.1M
↑ 16.69%
Q4 FY23Q/Q Change
Total Assets
234.3M
↑ 88.81%
Total Liabilities
145.6M
↑ 702.98%
Q1 FY24Q/Q Change
Total Assets
219.4M
↓ 6.35%
Total Liabilities
137.1M
↓ 5.84%
Q2 FY24Q/Q Change
Total Assets
243.3M
↑ 10.87%
Total Liabilities
143.3M
↑ 4.53%
FY18Y/Y Change
Operating Cash Flow
-12.6M
↓ 570.74%
Investing Cash Flow
-15.0M
↓ 1034.37%
Financing Cash Flow
29.9M
↑ 125.82%
FY19Y/Y Change
Operating Cash Flow
-285.0K
↓ 97.75%
Investing Cash Flow
-19.3M
↑ 28.62%
Financing Cash Flow
30.5M
↑ 1.85%
FY20Y/Y Change
Operating Cash Flow
10.1M
↓ 3641.05%
Investing Cash Flow
-209.0K
↓ 98.92%
Financing Cash Flow
19.8M
↓ 35.09%
FY21Y/Y Change
Operating Cash Flow
22.7M
↑ 124.71%
Investing Cash Flow
-26.5M
↑ 12579.43%
Financing Cash Flow
12.8M
↓ 35.15%
FY22Y/Y Change
Operating Cash Flow
-12.9M
↓ 156.79%
Investing Cash Flow
-20.2M
↓ 23.69%
Financing Cash Flow
-4.5M
↓ 134.68%
Q1 FY23Q/Q Change
Operating Cash Flow
-4.9M
↑ 26.58%
Investing Cash Flow
-7.2M
↓ 52.55%
Financing Cash Flow
-1.4M
↑ 3.48%
Q2 FY23Q/Q Change
Operating Cash Flow
-7.2M
↑ 46.39%
Investing Cash Flow
-4.5M
↓ 38.04%
Financing Cash Flow
-1.2M
↓ 14.84%

Technicals Summary

Sell

Neutral

Buy

Xoma Royalty Corp is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Xoma Royalty Corp
Xoma Royalty Corp
8.53%
13.87%
69.65%
24.21%
63.79%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.28%
10.06%
24.53%
74.0%
232.45%
Novo Nordisk A/s
Novo Nordisk A/s
-4.54%
-5.72%
21.59%
126.2%
349.01%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
8.87%
102.98%
82.67%
44.83%
241.09%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
5.0%
20.77%
31.37%
158.16%
163.17%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Xoma Royalty Corp
Xoma Royalty Corp
24.2
NA
-0.42
-0.12
-0.17
-0.07
NA
8.57
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.41
26.41
1.37
44.9
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
40.21
40.21
1.81
3.36
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.42
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.59
0.18
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Xoma Royalty Corp
Xoma Royalty Corp
Buy
$337.6M
63.79%
24.2
-119.61%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$110.0B
232.45%
26.41
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$529.8B
349.01%
40.21
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$38.1B
241.09%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$128.7B
163.17%
32.84
-4.74%

Insights on Xoma Royalty Corp

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.49M → 11.08M (in $), with an average increase of 86.6% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -20.10M → 15.98M (in $), with an average increase of 143.9% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 82.9% return, outperforming this stock by 10.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 44.8% return, outperforming this stock by 20.6%

Institutional Holdings

  • Bvf Inc

    31.05%

  • FMR Inc

    9.85%

  • BlackRock Inc

    4.38%

  • Vanguard Group Inc

    3.56%

  • Stonepine Capital Management Llc

    2.14%

  • Opaleye Management Inc

    2.14%

Company Information

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.

Organization
Xoma Royalty Corp
Employees
13
CEO
Mr. Owen P. Hughes Jr.
Industry
Health Technology

Discover More

FAQs